Ab­b­Vie puts up fight against Orilis­sa gener­ics from San­doz, Te­va and oth­ers

Sev­er­al drug­mak­ers, in­clud­ing San­doz and Te­va, are bank­ing on swift ap­provals for their gener­ic ver­sions of the en­dometrio­sis drug Orilis­sa — but not if Ab­b­Vie can help it.

The phar­ma gi­ant filed suit against the gener­ic com­peti­tors in Delaware fed­er­al court on Thurs­day, as­sert­ing sev­er­al patents, the lat­est of which ex­pire in 2036. Plain­tiffs ar­gued in a 167-page com­plaint that ab­bre­vi­at­ed NDAs sub­mit­ted by the de­fen­dants have caused or will lead to “fore­see­able harm and in­jury” to Ab­b­Vie.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER